Study Design
This multicenter, open-label, phase III randomized clinical trial was conducted between March 2017 and April 2020 in patients enrolled in 10 centers in China. The study was approved by the institutional review boards and independent ethics committees of the participating centers. The study was performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants. This study followed the Consolidated Standards of Reporting Trials (